BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ristoglogene autogetemcel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ristoglogene autogetemcel\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05456880-10266@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ristoglogene autogetemcel: Phase 1/2 readout est. (NCT05456880)
DESCRIPTION:Ristoglogene autogetemcel\, phase 1/2\, Sickle Cell Disease.\nS
 tudy: BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Pa
 tients With Severe Sickle Cell Disease\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ristogloge
 ne-autogetemcel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05456880
URL:https://assetmemo.bio/drug/ristoglogene-autogetemcel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
